



SHAREABLE PDF

# Potential of regulatory T-cell-based therapies in the management of severe COVID-19

Emmanuel Stephen-Victor <sup>1</sup>, Mrinmoy Das<sup>1</sup>, Anupama Karnam<sup>2</sup>,  
Bruno Pitard<sup>3</sup>, Jean-François Gautier<sup>2,4</sup> and Jagadeesh Bayry <sup>2</sup>

**Affiliations:** <sup>1</sup>Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. <sup>2</sup>Institut National de la Santé et de la Recherche Médicale; Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France. <sup>3</sup>Université de Nantes, CNRS ERL6001, Inserm 1232, CRCINA, Nantes, France. <sup>4</sup>Service de Diabétologie, Endocrinologie, Nutrition, Centre Universitaire du Diabète et de ses Complications, Hôpital Lariboisière, Université Paris-Diderot Paris-7, Paris, France.

**Correspondence:** Jagadeesh Bayry, Institut National de la Santé et de la Recherche Médicale Unité 1138, Centre de Recherche des Cordeliers, 15 rue de l'Ecole de Médecine, Paris, F-75006, France. E-mail: jagadeesh.bayry@crc.jussieu.fr



@ERSpublications

**In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T-cell-based therapies could be considered for patient management** <https://bit.ly/3eKqWPo>

**Cite this article as:** Stephen-Victor E, Das M, Karnam A, *et al.* Potential of regulatory T-cell-based therapies in the management of severe COVID-19. *Eur Respir J* 2020; 56: 2002182 [<https://doi.org/10.1183/13993003.02182-2020>].

This single-page version can be shared freely online.

## To the Editor:

“Cytokine storm”, inflammation-mediated severe lung damage and defective haemostasis are the main underlying reasons for morbidity and mortality in coronavirus disease 2019 (COVID-19) patients [1]. Several immunotherapies that target various inflammatory processes have been successfully used in COVID-19 patients and many other strategies are under evaluation [2, 3]. However, in view of dysregulated immune responses in severe COVID-19 patients, we suggest that CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> regulatory T-cell (Treg)-based strategies could be considered for patient management.